THC Biomed Intl Ltd. produces and sells medical and recreational cannabis in Canada. More Details
High growth potential with adequate balance sheet.
Share Price & News
How has THC Biomed Intl's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: THC is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: THC's weekly volatility (14%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: THC underperformed the Canadian Pharmaceuticals industry which returned 103.1% over the past year.
Return vs Market: THC underperformed the Canadian Market which returned 37.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is THC Biomed Intl's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StAnalysts Expect Breakeven For THC Biomed Intl Ltd. (CSE:THC) Before Long
3 months ago | Simply Wall StWould THC Biomed Intl (CSE:THC) Be Better Off With Less Debt?
7 months ago | Simply Wall StHere's Why THC Biomed Intl (CSE:THC) Can Afford Some Debt
Is THC Biomed Intl undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: THC (CA$0.14) is trading below our estimate of fair value (CA$2495.59)
Significantly Below Fair Value: THC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: THC is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.
PE vs Market: THC is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate THC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: THC is good value based on its PB Ratio (1.9x) compared to the CA Pharmaceuticals industry average (2.8x).
How is THC Biomed Intl forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: THC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).
Earnings vs Market: THC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: THC's is expected to become profitable in the next 3 years.
Revenue vs Market: THC's revenue (104% per year) is forecast to grow faster than the Canadian market (7.3% per year).
High Growth Revenue: THC's revenue (104% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if THC's Return on Equity is forecast to be high in 3 years time
How has THC Biomed Intl performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: THC is currently unprofitable.
Growing Profit Margin: THC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: THC is unprofitable, and losses have increased over the past 5 years at a rate of 23.5% per year.
Accelerating Growth: Unable to compare THC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: THC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.2%).
Return on Equity
High ROE: THC has a negative Return on Equity (-38.34%), as it is currently unprofitable.
How is THC Biomed Intl's financial position?
Financial Position Analysis
Short Term Liabilities: THC's short term assets (CA$5.8M) exceed its short term liabilities (CA$4.8M).
Long Term Liabilities: THC's short term assets (CA$5.8M) exceed its long term liabilities (CA$2.7M).
Debt to Equity History and Analysis
Debt Level: THC's debt to equity ratio (36.4%) is considered satisfactory.
Reducing Debt: THC's debt to equity ratio has reduced from 631.1% to 36.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: THC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if THC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is THC Biomed Intl current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate THC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate THC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if THC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if THC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of THC's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. John Miller serves as Chief Executive Officer at THC Biomed Intl Ltd. since April 29, 2015. He is also President at THC Biomed Intl Ltd. and its Director since June 3, 2014. He was Director and Office...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether John's total compensation is reasonable compared to companies of similar size in the Canadian market.
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Experienced Management: THC's management team is seasoned and experienced (5.8 years average tenure).
Experienced Board: THC's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.5%.
THC Biomed Intl Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: THC Biomed Intl Ltd.
- Ticker: THC
- Exchange: CNSX
- Founded: 2012
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$22.118m
- Shares outstanding: 163.84m
- Website: https://thcbiomed.com
Number of Employees
- THC Biomed Intl Ltd.
- 1340 St. Paul Street
- British Columbia
- V1Y 2E1
THC Biomed Intl Ltd. produces and sells medical and recreational cannabis in Canada. The company conducts research and development of products and services related to the medical cannabis industry. It also...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/06 23:06|
|End of Day Share Price||2021/05/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.